ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).American journal of hematology · 2026Pooled it
- Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation.Leukemia · 2023Trial
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.The New England journal of medicine · 2022Trial
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.Leukemia · 2026Article
- Article
- Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma.Cancers · 2026Article
- Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma.Targeted oncology · 2026Review
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma.Nature communications · 2026Article
- Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy.Frontiers in immunology · 2026Review
- Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study.Blood research · 2025Article
- Article
- Role of Composite Measurable Residual Disease Assessment with PET-CT and flow cytometry in Multiple Myeloma patients undergoing Autologous Transplant.Blood cell therapy · 2025Article
- Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma.Blood cancer journal · 2025Observational
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Cytogenetic risk stratification combined with minimal residual disease status influences the therapeutic outcome and prognosis of multiple myelomas.Scientific reports · 2025Article
- Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.Blood advances · 2025Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
Abstract
purposeMinimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points in the context of maintenance therapy after autologous stem-cell transplant (ASCT) and the interaction between MRD and molecular risk.
methodsData from a large phase III trial (Myeloma XI) were examined to determine the relationship between MRD status, progression-free survival (PFS), and overall survival (OS) in post-ASCT patients randomly assigned to lenalidomide maintenance or no maintenance at 3 months after ASCT. MRD status was assessed by flow cytometry (median sensitivity 0.004%) before maintenance random assignment (ASCT + 3) and 6 months later (ASCT + 9).
resultsAt ASCT + 3, 475 of 750 (63.3%) patients were MRD-negative and 275 (36.7%) were MRD-positive. MRD-negative status was associated with improved PFS (hazard ratio [HR] = 0.47; 95% CI, 0.37 to 0.58
conclusionIn patients with multiple myeloma, MRD status at both ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.